Related Tags >> Generic drugs Avonex Teva Pharmaceutical Tysabri

Copaxone News

Most Popular Copaxone Story

Will Teva join Big Pharma by 2015?

January 8, 2010 — 9:39am ET | By Tracy Staton

Five years, twice the revenue. That's what Teva Pharmaceutical Industries chief Shlomo Yanai is predicting: By 2015 his feisty generics company can more than double its annual sales to $31 billion. Read more...

Copaxone Press Releases

Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm Modifications According to a Recent BioTrends
While Copaxone and Interferon-Betas Continue to Dominate Treatment in MS, Tysabri Shows Modest Increase in First-Line Use
Critical Therapeutic Objectives Continue to go Unmet for the Treatment of Multiple Sclerosis Even with the Assimilation of
Remicade, Humira and Enbrel Accounted for 40.1% of the Immunomodulators Market in 2010: companiesandmarkets.com
Teva to Present at the Goldman Sachs 32nd Annual Global Healthcare Conference

Latest Headlines

Teva U.S. sales plummet, Copaxone sets record
November 2, 2011
Copaxone patent fight set for court Sept. 7
August 30, 2011
Can Big Pharma and generics makers switch their spots?
July 26, 2011
Teva gets a taste of its own patent-challenge medicine
July 25, 2011
Facing Copaxone rivals, Teva looks to buy
February 9, 2011
Teva downplays Copaxone copying as sales rise
July 27, 2010
Teva talks healthcare reform, Copaxone
May 13, 2010
Biogen, Elan launch MS drug face-off
March 25, 2010
Teva posts 28% rise in Q4 profits
February 16, 2010
Will Teva join Big Pharma by 2015?
January 8, 2010
Teva faces double Copaxone woes
July 14, 2008
Mylan to sell copycat of Teva MS drug
June 10, 2008

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Hottest Products

Featured Jobs

Events